What return and destruction rules apply to unused opioids in Canadian pharmacies: how Ontario R.R.O. 1990 Reg. 347 and provincial rules compares with state medical-waste rules and EPA guidance

A folded stack of 30 gallon waste bags, shown in the green format used for general refuse

What return and destruction rules apply to unused opioids in Canadian pharmacies: how Ontario R.R.O. 1990 Reg. 347 and provincial rules compares with state medical-waste rules and EPA guidance

A blister pack of hydromorphone comes back to a pharmacy counter in a clear bag with three tablets missing and no paperwork. One staff member reaches for the biomedical waste container, because a drug feels clinical. Another reaches for the return bin, because a controlled substance does not go into a waste bag while it is still a controlled substance. Both instincts are half right, and the half that is wrong is the part an auditor asks about.

Two legal systems meet on that counter and neither cancels the other. Federal drug law decides who may hold the tablets and what counts as destroyed. Provincial waste law decides what happens to the material once it has stopped being a drug, which container it goes into, and what paperwork follows the truck. A pharmacy that applies only one of the two either loses its audit trail or pushes a controlled substance into a stream that cannot lawfully accept it.

This guide separates the two systems as they operate in Ontario, then sets the same steps against the American rules a US site follows. The step that goes wrong most often is the first one, which is deciding which rule is being asked.

Which rule applies to an unused opioid, the drug law or the waste regulation?

Both, in sequence, and the order matters. While the tablets are in the pharmacy's possession and still identifiable as a controlled substance, the Controlled Drugs and Substances Act and the regulations under it govern them. Destruction under those rules means altering or denaturing the substance until consumption is impossible or improbable, and the act is a witnessed, recorded event.

The waste regulation begins where the object stops being a dose. Ontario's R.R.O. 1990, Reg. 347 is made under the Environmental Protection Act and does the classifying: it defines hazardous waste, sets the monthly thresholds that separate a small producer from a full generator, and requires subject waste to move on a manifest. It contains no clause about unused tablets, and it does not define biomedical waste at all. That definition sits in the ministry guideline known as C-4, which lists the categories a generator has to segregate and treat.

A returned tablet has no category there either. What the return bench does consume is the one-quart puncture-resistant sharps container for the glass that comes back with injectable products, such as a broken ampoule or a needle still in its packaging, because sharp items are a named category and the container is the control.

Where does a returned opioid sit in the C-4 table?

C-4 category What it covers Does a returned opioid tablet fit?
Human anatomical waste Tissues, organs, body parts No
Human blood waste Liquid blood, saturated items, body fluid visibly containing blood Only if the return is blood-contaminated
Microbiology laboratory waste Cultures and laboratory stock No
Sharps waste Needles, blades, broken glass that can cut Yes, for the glass and needles that come back
Cytotoxic waste Cytotoxic drugs and medicinal chemicals, with contaminated tubing, vials and gloves Depends on the drug and on how the medicinal chemical clause is read
Animal anatomical and blood waste Veterinary and research material No

The practical reading is that the return stream is a drug stream first and a waste stream second. A pharmacy that starts from the waste table ends up arguing about bag colour for material that should never have reached a bag in one piece.

How does an Ontario pharmacy destroy unserviceable stock and post-consumer returns?

There are two lawful routes, and both start with a record rather than a container.

The first is transfer to a dealer authorized to destroy controlled substances. The dealer issues a signed and dated written order naming the substance, its form, strength and quantity, the pharmacy's address and the purpose, which is destruction. The material leaves in a sealed, marked, tamper-evident container and the transaction is entered in the pharmacy's record.

A puncture-resistant one-quart sharps container with a locking lid and a restricted drop opening

The second is local destruction. The pharmacy alters or denatures the substance until consumption is impossible or improbable, does so in the presence of another health professional, and both people sign and date a statement attesting to it. The working record is written before the event: date, drug name, strength per unit, quantity, and the names of the two people present. College guidance asks for the record to be kept at least two years, and the method has to comply with environmental law, which is where the drug rules and the waste rules touch.

Federal practice has moved toward speed. Pre-authorization for local destruction of unserviceable narcotics and controlled drugs is no longer required, so a pharmacy can act on its own schedule instead of waiting for an acknowledgment and leaving a full return bin in a back room.

Ontario adds a return duty at the counter for one product family. Under the patch-for-patch arrangement described by the college, a dispenser hands over new fentanyl patches only in exchange for the used ones, examines and documents what came back, and stores the returned patches securely until destruction. That is a return rule rather than a destruction rule, which is why the two belong in separate lines of a procedure.

What does the DEA require of a US pharmacy holding the same bottle?

The American side splits the same job differently, and the split is explicit. Disposal is federal drug enforcement; classification is federal waste law with state overlays.

Under 21 CFR 1317.05, a registered practitioner holding controlled substances it no longer needs has four routes: destroy promptly on site, deliver promptly to a reverse distributor's registered location, deliver for return or recall to the person or manufacturer it came from, or ask the DEA for assistance using the disposal form. Every route begins with prompt action, which is the operative word for an inspector.

Whichever route is chosen, the substance has to be rendered non-retrievable, meaning the drug cannot be recovered for use. On-site destruction carries a two-person rule: under 21 CFR 1317.95, two employees of the registrant must handle or observe the handling until the substance is non-retrievable, and two employees must personally witness the destruction. The same rule applies to loading and unloading during a transfer.

A reverse distributor is a registered entity, not a waste hauler. That distinction is worth repeating because the two industries look alike from a loading dock.

Where do state medical-waste rules and EPA guidance come in?

At the classification step, and only for the subset of drugs the environmental rules actually reach.

The healthcare facility standards in 40 CFR Part 266 Subpart P apply to hazardous waste pharmaceuticals, which means drugs listed in the P or U lists at 40 CFR 261.33 or carrying a hazardous characteristic. The familiar examples are epinephrine, warfarin, nicotine and several chemotherapy agents. A drug is looked up rather than guessed, and a facility that sorts by drug class will get the determination wrong in both directions.

Two provisions matter most for a pharmacy with a return bin. One is the prohibition on sewering hazardous waste pharmaceuticals, which reaches every healthcare facility and every reverse distributor, including very small quantity generators that otherwise sit outside the subpart. The other is the conditional exemption for hazardous waste pharmaceuticals that are also controlled substances, which lets the two regimes be managed together instead of on parallel paperwork.

A folded stack of 30 gallon waste bags, shown in the green format used for general refuse

State programmes sit above the federal floor. Under 40 CFR Part 271, authorized states run their own hazardous waste programmes and may be more stringent, and a state medical-waste programme writes its own definition of regulated medical waste. A pharmacy therefore reads the definition for its address rather than assuming that loose tablets are medical waste, or that they are not.

The EPA guidance is where the operating practice is written down. The 10-Step Blueprint for healthcare facilities walks through the determination, the P and U lists, drain disposal and reverse distributors, and is revised to match the current subpart. Its most useful line for a buyer is structural: a reverse distributor is a credit mechanism, not a waste management service, so the facility still needs a hazardous waste determination and a waste vendor for material that fails the credit test.

Which steps actually differ between the two countries?

Step Ontario, Canada United States
Legal basis for destruction Controlled Drugs and Substances Act and provincial college guidance 21 CFR Part 1317 under DEA registration
Standard the drug must reach Altered or denatured, consumption impossible or improbable Rendered non-retrievable
Witness Another health professional present, joint signed statement Two employees observe handling, two personally witness
Record Written before destruction, kept at least two years Registrant records, disposal form where a route requires it
Off-site route Dealer authorized to destroy, on a signed written order Registered reverse distributor
Waste classification Provincial regulation plus the C-4 category list Listed or characteristic hazardous waste under the subpart
Sewer route Closed by environmental rules and by the denaturing test Explicitly prohibited for hazardous waste pharmaceuticals
Who writes the waste definition Province, through regulation and guideline State medical-waste programme, on a federal floor

Which three assumptions go wrong most often?

The first is that a drug is biomedical waste because it came from a patient. In Ontario the category list is specific and a returned tablet is not on it. Starting from the bag instead of from the drug rules produces a stream that cannot be traced back to a destruction event.

The second is that the environmental regulator authorizes destruction. It does not. The EPA and the state programmes decide what may be discarded and how; the drug enforcement framework decides how the substance must be destroyed and who has to watch. Reversing the two leaves a site with a witness statement nobody asked for and no waste determination at all.

The third is that a reverse distributor replaces a waste vendor. The EPA guidance is direct on this point: credit and destruction are the service, and the hazardous waste determination still belongs to the facility. Sites that treat the reverse distributor as their waste programme discover the gap during an inspection rather than during a pickup.

What does the return bench actually consume?

Three consumables, and none of them is the destruction container. The container for material bound to a dealer arrives with the dealer's order and has to be sealed and tamper-evident, so it is not a catalogue purchase.

What the bench buys is the handling layer. Nitrile examination gloves, 1,000 to a case, for unpacking and sorting returns that carry whatever was in the patient's bathroom cabinet. A sharps container for the glass and needles, the one part of the stream that is a named waste category in its own right. And a liner for packaging, leaflets and cartons, which are general refuse and stay general refuse, since compostable 30 gallon waste bags change the material of the bag and not the class of the waste.

Ordering for a pharmacy group or a multi-site care organization? Wholesale and multi-site ordering covers case pricing and account setup, and the B2B wholesale collection lists the lines stocked for institutional buyers. Reselling? become a distributor.

How should a group write this into a procedure?

Six lines carry it. Name who holds the return bin and who may sign a destruction statement. Write the denaturing standard for each dosage form, including liquids and patches, and say what happens to the packaging. Set a maximum dwell time for the bin, because an unbounded dwell time is a diversion risk rather than an efficiency measure. Keep the destruction record and the manifest in separate files, since one proves the drug is gone and the other proves the waste moved lawfully. Record which C-4 category contaminated items fall into. And name who makes the hazardous waste determination on the American side, so the answer is not discovered during an inspection.

For a group operating in both countries, write two procedures and one shared glossary. The glossary is what stops a Canadian manager from calling a dealer order a manifest, and an American manager from calling a reverse distributor a waste vendor.

References

  1. R.R.O. 1990, Reg. 347: General - Waste Management, Environmental Protection Act, Ontario (checked 8 November 2026)
  2. Environmental Protection Act, R.S.O. 1990, c. E.19 (checked 8 November 2026)
  3. Guideline C-4: The Management of Biomedical Waste in Ontario (checked 8 November 2026)
  4. Controlled Drugs and Substances Act, S.C. 1996, c. 19 (checked 8 November 2026)
  5. Narcotic Control Regulations, C.R.C., c. 1041 (checked 8 November 2026)
  6. Controlled Substances: Destruction of Unserviceable Stock and Post-Consumer Returns, New Brunswick College of Pharmacists fact sheet adapted from the Ontario College of Pharmacists (checked 8 November 2026)
  7. Patch-For-Patch Fentanyl Return Program, Ontario College of Pharmacists fact sheet (checked 8 November 2026)
  8. 21 CFR Part 1317, Disposal of Controlled Substances (checked 8 November 2026)
  9. 21 CFR 1317.90, Methods of destruction (checked 8 November 2026)
  10. 21 CFR 1317.95, Destruction procedures (checked 8 November 2026)
  11. 40 CFR Part 266 Subpart P, Hazardous Waste Pharmaceuticals (checked 8 November 2026)
  12. 40 CFR 266.505, Prohibition on sewering hazardous waste pharmaceuticals (checked 8 November 2026)
  13. 40 CFR 266.506, Conditional exemption for hazardous waste pharmaceuticals that are also controlled substances (checked 8 November 2026)
  14. 40 CFR 261.33, Discarded commercial chemical products, off-specification species, container residues and spill residues (P and U lists) (checked 8 November 2026)
  15. 40 CFR 262.11, Hazardous waste determination and recordkeeping (checked 8 November 2026)
  16. 40 CFR Part 271, Requirements for authorization of state hazardous waste programs (checked 8 November 2026)
  17. Managing Pharmaceutical Waste: A 10-Step Blueprint for Healthcare Facilities, US Environmental Protection Agency (checked 8 November 2026)
  18. Drug Disposal, Diversion Control Division, US Drug Enforcement Administration (checked 8 November 2026)

Printable companion: the downloadable destruction and manifest log carries the same fields as the record the regulations ask for, so the entry is written at the bench rather than rebuilt from memory at audit time.

Working out how many containers and liners a month of returns actually needs? The clinic supply and cost planner turns a weekly return volume into cases per quarter.

Related Reading

Frequently Asked Questions

Does Ontario Regulation 347 apply to a bottle of unused opioid tablets?

Reg. 347 is a waste regulation. It classifies waste and sets manifest duties for subject waste, but the tablets are a controlled substance while they are still in the pharmacy's possession, so the federal drug rules govern the return and the destruction first. The provincial regulation governs the material that leaves afterwards.

Are unused opioids biomedical waste in Ontario?

Not by definition. The list of biomedical waste categories sits in Guideline C-4 rather than in Reg. 347, and it covers anatomical waste, human and animal blood, microbiology laboratory waste, sharps and cytotoxic waste. A tablet has no clause of its own, so it becomes a waste question only after it has been destroyed or sent for destruction.

Who has to witness a destruction in Canada?

The federal guidance asks the pharmacy to destroy in the presence of another health professional, with both people recording their names and the date on a joint statement. The provincial college fact sheets repeat that expectation and add that the record is kept for at least two years.

What does destroyed mean in the Canadian rules?

The substance has to be altered or denatured to the point where consumption is impossible or improbable. Pouring tablets into a sink does not meet that test and also breaches the environmental rules that apply to the drain.

Does a US pharmacy need a reverse distributor?

Not necessarily. A registrant may destroy on site, deliver to a reverse distributor, return the substance for recall, or ask the DEA for assistance. What it may not do is store the material indefinitely while it decides, because each route begins with the word promptly.

How many people have to watch a DEA destruction?

Two employees of the registrant must handle or observe the handling until the substance is rendered non-retrievable, and two employees must personally witness the destruction. The rule applies to on-site destruction and to a transfer to a site registered for destruction.

Is every unused opioid a hazardous waste under EPA rules?

No. The healthcare facility standards apply to drugs that are listed or that carry a hazardous characteristic, which is why the drug is looked up in the P and U lists rather than sorted by drug class. A discarded opioid that is not listed and shows no characteristic is managed under other rules, including the state medical-waste programme.

Can a pharmacy flush liquid opioid residue to avoid the paperwork?

No. The EPA prohibition on sewering hazardous waste pharmaceuticals reaches every healthcare facility and every reverse distributor, including very small quantity generators, and it applies whether or not the site has notified under the subpart.

Last updated: October 2026. CliniEco Medical is a licensed medical device establishment (MDEL #35334).

Vous travaillez déjà avec des cliniques ? Devenez représentant régional.